Alto NeuroscienceANRO
About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Employees: 88
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
3% more funds holding
Funds holding: 75 [Q3] → 77 (+2) [Q4]
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
1.64% less ownership
Funds ownership: 85.18% [Q3] → 83.54% (-1.64%) [Q4]
48% less call options, than puts
Call options by funds: $136K | Put options by funds: $260K
64% less capital invested
Capital invested by funds: $266M [Q3] → $95.3M (-$170M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ANRO.
Financial journalist opinion
Based on 15 articles about ANRO published over the past 30 days









